impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

Mental health symptoms in scleroderma during COVID-19: a Scleroderma Patient-centred Intervention Network (SPIN) cohort longitudinal study

1, 2, 3, 4, 5, 6, 7, 8, 9
Collaborator/s: C. Fortuné1, A. Gietzen2, G. Guillot3, N. Lewis4, K. Nielsen5, M. Richard6, M. Sauvé7, J. Welling8, C.E. Adams9, C.E. Adams10, K. Gottesman11, M. Hudson12, L.K. Hummers13, A. Lawrie-Jones14, V.L. Malcarne15, M.D. Mayes16, W.R. Nielson17, S. Assassi18, G. El-Baalbaki19, C. Van Den Ende20, K. Fligelstone21, T.M. Frech22, D. Harel23, M. Hinchcliff24, S.R. Johnson25, M. Larche26, C. Leite27, C. Nguyen28, J. Pope29, F. Rannou30, T.S. Rodriguez-Reyna31, A.A. Schouffoer32, M.E. Suarez-Almazor33, C. Agard34, N.A. Abdallah35, M. André36, E.J. Bernstein37, S. Berthier38, L. Bissonnette39, A. Bruns40, P. Carreira41, M. Casadevall42, B. Chaigne43, L. Chung44, B. Crichi45, C.P. Denton46, R. Domsic47, J.V. Dunne48, B. Dunogue49, R. Fare50, D. Farge-Bancel51, P.R. Fortin52, J. Gordon53, B. Granel-Rey54, A. Guffroy55, G. Gyger56, E. Hachulla57, S. Hoa58, A. Ikic59, N. Jones60, S. Kafaja61, N. Khalidi62, K. Lakin63, M. Lambert64, D. Launay65, Y.C. Lee66, H. Maillard67, N. Maltez68, J. Manning69, I. Marie70, M. Martin Lopez71, T. Martin72, A. Masetto73, F. Maurier74, A. Mekinian75, S. Melchor Díaz76, M. Nikpour77, L. Olagne78, V. Poindron79, S. Proudman80, A. Régent81, S. Rivière82, D. Robinson83, E. Rodriguez Almazar84, S. Roux85, P. Smets86, V. Sobanski87, R. Spiera88, V. Steen89, E. Sutton90, C. Thorne91, P. Wilcox92, M. Cañedo Ayala93, V. Cook94, S. Hu95, E.-L. Nassar96, M.A. Neyer97, J. Nordlund98, S. Provencher99

 

  1. Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, and Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
  2. Department of Clinical Psychology, Radboud University, Nijmegen; Department of Medical Psychology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen; IQ Healthcare, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen; and Radboudumc Center for Mindfulness, Department of Psychiatry, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  3. Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.
  4. Department of Community Health Sciences, University of Calgary, Alberta; Hotchkiss Brain Institute, University of Calgary, Alberta; and O’Brien Institute for Public Health, University of Calgary, Alberta, Canada.
  5. Department of Medicine, McGill University, Montreal; and Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
  6. Service de Médecine Interne, Centre de Référence Maladies Autoimmunes Systémiques Rares d’Ile de France, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris (AP-HP), and APHP-CUP, Hôpital Cochin, Paris, Université de Paris, France.
  7. Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA.
  8. Department of Medicine, McGill University, Montreal; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal; and Respiratory Epidemiology and Clinical Research Unit, McGill University Health Centre, Montreal, Quebec, Canada.
  9. Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal; Department of Psychiatry, McGill University, Montreal; Department of Medicine, McGill University, Montreal; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal; Department of Psychology, McGill University, Montreal; and Biomedical Ethics Unit, McGill University, Montreal, Quebec, Canada. brett.thombs@mcgill.ca

  1. Ottawa Scleroderma Support Group, Ottawa, Ontario, Canada
  2. National Scleroderma Foundation, Tri-State Chapter, Binghamton, New York, USA.
  3. Sclérodermie Québec, Longueuil, Quebec, Canada.
  4. Toronto, Ontario, Canada.
  5. Scleroderma Society of Ontario, Ottawa, Ontario, Canada.
  6. Scleroderma Atlantic, Halifax, Nova Scotia, Canada.
  7. Scleroderma Society of Ontario, Hamilton, Ontario, Canada.
  8. NVLE Dutch patient organization for systemic autoimmune diseases, Utrecht, the Netherlands.
  9. Jewish General Hospital, Montreal, Quebec, Canada.
  10. Jewish General Hospital, Montreal, Quebec, Canada.
  11. National Scleroderma Foundation, Los Angeles, CA, USA.
  12. McGill University, Montreal, Quebec, Canada.
  13. Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  14. Scleroderma Australia and Scleroderma Victoria, Melbourne, Victoria, Australia.
  15. San Diego State University, San Diego, CA, USA
  16. University of Texas McGovern School of Medicine, Houston, TX, USA.
  17. St. Joseph’s Health Care, London, Ontario, Canada.
  18. University of Texas McGovern School of Medicine, Houston, Texas, USA.
  19. Université du Québec à Montréal, Montreal, Quebec, Canada.
  20. Sint Maartenskliniek, Nijmegen, the Netherlands.
  21. Scleroderma & Raynaud’s UK, London, UK.
  22. University of Utah, Salt Lake City, Utah, USA.
  23. New York University, New York, NY, USA.
  24. Yale School of Medicine, New Haven, Connecticut, USA.
  25. Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, and University of Toronto, Toronto, Ontario, Canada.
  26. McMaster University, Hamilton, Ontario, Canada.
  27. University of Minho, Braga, Portugal.
  28. Université Paris Descartes, Université de Paris, and Assistance Publique - Hôpitaux de Paris, France.
  29. University of Western Ontario, London, Ontario, Canada.
  30. Université Paris Descartes, Université de Paris, and Assistance Publique - Hôpitaux de Paris, France.
  31. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  32. Leiden University Medical Center, Leiden, the Netherlands.
  33. University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  34. Centre Hospitalier Universitaire - Hôtel-Dieu de Nantes, France.
  35. Assistance Publique - Hôpitaux de Paris, Hôpital St-Louis, Paris, France.
  36. Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France.
  37. Columbia University, New York, NY, USA.
  38. Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France.
  39. Université de Sherbrooke, Quebec, Canada.
  40. Université de Sherbrooke, Quebec, Canada.
  41. Servicio de Reumatologia del Hospital 12 de Octubre, Madrid, Spain.
  42. Assistance Publique - Hôpitaux de Paris, Hôpital Cochin, Paris, France.
  43. Assistance Publique - Hôpitaux de Paris, Hôpital Cochin, Paris, France.
  44. Stanford University, Stanford, CA, USA.
  45. Assistance Publique - Hôpitaux de Paris, Hôpital St-Louis, Paris, France.
  46. Royal Free London Hospital, London, UK.
  47. University of Pittsburgh, PA, USA.
  48. St. Paul's Hospital and University of British Columbia, Vancouver, BC, Canada.
  49. Assistance Publique - Hôpitaux de Paris, Hôpital Cochin, Paris, France.
  50. Servicio de Reumatologia del Hospital 12 de Octubre, Madrid, Spain.
  51. Assistance Publique - Hôpitaux de Paris, Hôpital St-Louis, Paris, France.
  52. CHU de Québec - Université Laval, Quebec, Canada.
  53. Hospital for Special Surgery, New York City, NY, USA.
  54. Aix Marseille Université, and Assistance Publique - Hôpitaux de Marseille, Hôpital Nord, Marseille, France.
  55. Les Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, Strasbourg, France.
  56. Jewish General Hospital and McGill University, Montreal, Quebec, Canada.
  57. Centre Hospitalier Régional Universitaire de Lille, Hôpital Claude Huriez, Lille, France.
  58. Centre Hospitalier de l’Uuniversité de Montréal - CHUM, Montreal, Quebec, Canada.
  59. CHU de Québec - Université Laval, Quebec, Canada.
  60. University of Alberta, Edmonton, Alberta, Canada.
  61. University of California, Los Angeles, CA, USA.
  62. McMaster University, Hamilton, Ontario, Canada.
  63. Hospital for Special Surgery, New York City, NY, USA.
  64. Centre Hospitalier Régional Universitaire de Lille, Hôpital Claude Huriez, Lille, France.
  65. Centre Hospitalier Régional Universitaire de Lille, Hôpital Claude Huriez, Lille, France.
  66. Northwestern University, Chicago, Illinois, USA.
  67. Centre Hospitalier Régional Universitaire de Lille, Hôpital Claude Huriez, Lille, France.
  68. University of Ottawa, Ontario, Canada.
  69. Salford Royal NHS Foundation Trust, Salford, UK.
  70. CHU Rouen, Hôpital de Bois-Guillaume, Rouen, France.
  71. Servicio de Reumatologia del Hospital 12 de Octubre, Madrid, Spain.
  72. Les Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, Strasbourg, France.
  73. Université de Sherbrooke, Quebec, Canada.
  74. Uneos - Groupe Hospitalier Associatif, Metz, France.
  75. Assistance Publique - Hôpitaux de Paris, Hôpital St-Antoine, Paris, France.
  76. Servicio de Reumatologia del Hospital 12 de Octubre, Madrid, Spain.
  77. St Vincent’s Hospital and University of Melbourne, Victoria, Australia.
  78. Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France.
  79. Les Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, Strasbourg, France.
  80. Royal Adelaide Hospital and University of Adelaide, Adelaide, South Australia, Australia.
  81. Assistance Publique - Hôpitaux de Paris, Hôpital Cochin, Paris, France.
  82. Assistance Publique - Hôpitaux de Paris, Hôpital St-Antoine, Paris, France.
  83. University of Manitoba, Winnipeg, Manitoba, Canada.
  84. Servicio de Reumatologia del Hospital 12 de Octubre, Madrid, Spain.
  85. Université de Sherbrooke, Quebec, Canada.
  86. Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France.
  87. Centre Hospitalier Régional Universitaire de Lille, Hôpital Claude Huriez, Lille, France.
  88. Hospital for Special Surgery, New York City, NY, USA.
  89. Georgetown University, Washington, DC, USA.
  90. Dalhousie University, Halifax, Nova Scotia, Canada.
  91. Southlake Regional Health Centre, Newmarket, Ontario, Canada.
  92. St. Paul's Hospital and University of British Columbia, Vancouver, BC, Canada.
  93. Jewish General Hospital, Montreal, Quebec, Canada.
  94. Jewish General Hospital, Montreal, Quebec, Canada.
  95. Jewish General Hospital, Montreal, Quebec, Canada.
  96. Jewish General Hospital, Montreal, Quebec, Canada.
  97. Jewish General Hospital, Montreal, Quebec, Canada.
  98. Jewish General Hospital, Montreal, Quebec, Canada.
  99. Jewish General Hospital, Montreal, Quebec, Canada.

SPIN COVID-19 Patient Advisory Team for the SPIN Investigators

CER16515
2023 Vol.41, N°8
PI 1639, PF 1643
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 37083160 [PubMed]

Received: 12/01/2023
Accepted : 13/04/2023
In Press: 19/04/2023
Published: 03/08/2023

Abstract

OBJECTIVES:
People with systemic sclerosis (SSc) are vulnerable in COVID-19 and face challenges related to shifting COVID-19 risk and protective restrictions. We evaluated mental health symptom trajectories in people with SSc through March 2022.
METHODS:
The longitudinal Scleroderma Patient-centred Intervention Network (SPIN) COVID-19 cohort was launched in April 2020 and included participants from the ongoing SPIN Cohort and external enrolees. Analyses included estimated means with 95% CIs for anxiety and depression symptoms pre-COVID-19 for ongoing SPIN Cohort participants and anxiety, depression, loneliness, and fear of COVID-19 for all participants across 28 COVID-19 assessments up to March 2022. We conducted sensitivity analyse including estimating trajectories using only responses from participants who completed >90% of items for ≥21 of 28 possible assessments (“completers”) and stratified analyses for all outcomes by sex, age, country, and SSc subtype.
RESULTS:
Anxiety symptoms increased in early 2020 but returned to pre-COVID-19 levels by mid-2020 and remained stable through March 2022. Depression symptoms did not initially change but were slightly lower by mid-2020 compared to pre-COVID-19 and were stable through March 2022. COVID-19 fear started high and decreased. Loneliness did not change across the pandemic. Results were similar for completers and for all subgroups.
CONCLUSIONS:
People with SSc continue to face COVID-19 challenges related to ongoing risk, the opening of societies, and removal of protective restrictions. People with SSc, in aggregate, appear to be weathering the pandemic well, but health care providers should be mindful that some individuals may benefit from mental health support.

DOI: https://doi.org/10.55563/clinexprheumatol/cca0xv

Rheumatology Article

Rheumatology Addendum